Moderate
Established
Description
Carbamazepine, a potent enzyme inducer, significantly reduces sertraline plasma concentrations, potentially impairing antidepressant efficacy.
Mécanisme
Carbamazepine induces CYP3A4 and CYP2C19, accelerating sertraline metabolism and lowering its AUC by up to 65%, reducing antidepressant effect.
Signification clinique
Sertraline plasma levels may be reduced below therapeutic thresholds; loss of antidepressant efficacy and worsening depression risk.
Prise en charge
Monitor antidepressant response closely; sertraline dose increases may be required, or an alternative not metabolized by CYP3A4 should be considered.